Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration-Reference-Cited by-同舟云学术

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration

Published:2017-08-15 Issue:7 Volume:318 Page:626
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Naci Huseyin¹,Smalley Katelyn R.¹,Kesselheim Aaron S.²

Affiliation:

1. LSE Health, Department of Health Policy, London School of Economics and Political Science, London, England

2. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval;Journal of Pharmaceutical Innovation;2024-09-04

2. Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions;Pediatric Drugs;2024-08-05

3. New Oncologic Drugs from 2008 to 2023—Differences in Approval and Access between the United States, Europe and Brazil;Current Oncology;2024-08-02

4. Characteristics of Clinical Trials for the US Food and Drug Administration Accelerated Approval and Subsequent Confirmatory Trials: Implications for Drug Approval in Japan;Biological and Pharmaceutical Bulletin;2024-07-23

5. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07